Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    In-Person

    What is this Study about?

    The Nighttime Insomnia Treatment and Education for Canadians with Alzheimer’s Disease (NITE-CAD) team is lifestyle intervention program to support care partners in helping improve sleep in people living with dementia. This program is based on an American program that has been modified to meet the needs of Canadians. The NITE-CAD program takes place over 6-weeks and consists of 1) education and goal setting, 2) self-directed physical activity, and 3) bright light exposure. This study is to help ensure the NITE-CAD program is feasible for future offerings.

    Eligibility Criteria

    • Care partner to someone living with dementia with sleep difficulties

    • Are living with dementia experiencing sleep difficulties, with a live-in care partner who is interested in participating

    • Able to speak and understand English

    • Have access to the internet and a computer with a camera and microphone

    • Able to participate in an exercise program

    • Sufficient cognitive function to follow two-step commands.

    Recruitment End Date

  • Observational Study
    Online

    What is this Study about?

    Surveying opinions on how to improve diversity in dementia research.

    Eligibility Criteria

    You are eligible to participate if you are:

    1) Involved in dementia research or services

    AND / OR

    2) from an underserved group* in dementia research.

    3)Aged 19 +

    3)Able to complete the web-based survey in one of the following languages: English, French, Chinese (simplified), Punjabi, Inuktitut.

    *Underserved groups in dementia research include: Racial/ethnic minorities (i.e., South Asian, Chinese, Black, Filipino, Arab, Latin American, Southeast Asian, West Asian, Korean, Japanese, or other racial/ethnic minority) Indigenous populations (i.e., First Nations, Inuit, Métis, or other Indigenous group), Sexual/gender minorities (i.e., the LGBTQ2S+ community), Individuals living in rural and/or remote communities, Individuals living with a disability, Individuals with low social and economic conditions.

    Recruitment End Date

  • Observational Study
    Online & In-Person

    What is this Study about?

    A dementia diagnosis impacts the cognitive, functional, and physical abilities of those diagnosed, which will influence their ability to perform activities of daily living including meal preparation and eating. Persons living with dementia can experience a range of difficulties while eating that will impact their ability to consume adequate food and fluids, which include but are not limited to swallowing, chewing, and self-feeding difficulties. Consequently, persons living with dementia are at increased risk of malnutrition and negative health outcomes. The objective of this study is to understand the experience of persons’ living with dementia or diagnosed memory problems and/or their caregivers in managing eating challenges and swallowing problems in the community.

    Eligibility Criteria

    You are eligible to participate if you:
    - Speak English
    - A person with memory problems experiencing eating challenges or swallowing problems in the community
    - OR if you are or were a caregiver to a person with memory problems with eating challenges or swallowing problems.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

    Eligibility Criteria

    Age 50 - 85
    Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
    Must have a study partner

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.

    Eligibility Criteria

    60+
    Diagnosis of Alzheimer's disease
    Must have a study partner

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.

    Eligibility Criteria

    You are eligible to participate if you meet the following criteria:

    • Age ≥ 55; females must be post-menopausal

    • DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)

    • sMMSE ≤ 24

    • Clinically significant agitation based on IPA definition

    • Stable cognition-enhancing medication for at least 3 months prior to study enrolment

    • Availability of a caregiver to accompany participant to study visits and to participate in the study

    • Ability to speak English

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.

    Eligibility Criteria

    Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.

    Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.

    Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.

    Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.

    Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.

    Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.

    Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.

    Have not undergone any significant head trauma or surgery in the past 6 months.

    Are not pregnant or planning to become pregnant during the duration of the study.

    Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.

    Ability to speak English and French

    Recruitment End Date

  • Observational Study
    Online

    What is this Study about?

    Our overall goal is to improve the surgical experience for older adults with cognitive decline, including people with Alzheimer's and related dementias, their families, and caregivers.

    The aim of this study is to understand and describe the experiences of patients, families, and healthcare providers with postoperative delirium (delirium after surgery), and to identify strategies to support patient and family centered care for patients with postoperative delirium. We will conduct interviews with patients, families, and healthcare providers to describe their experiences with postoperative delirium.

    Our findings will be used to inform the development of a strategy for reducing delirium after surgery.

    Eligibility Criteria

    1) are a patient aged over 65 years who has experienced postoperative delirium (delirium after surgery), or

    2) are a caregiver/family member of a person who has experienced postoperative delirium (delirium after surgery)

    Ability to speak English

    Recruitment End Date

  • Observational Study
    Online

    What is this Study about?

    Older adults with normal cognition, mild impairments, and mild dementia can benefit from physical activity. This may be due to factors such as cognitive impairments (memory related), hearing and vision impairments, social factors (stigma, gender) and biological factors (cardiovascular disease, diabetes...etc). But we are not sure how these factors interact to impact physical activity. Therefore, the purpose of this study is to understand the interactions of these factors and thereby increase physical activity participation in older adult populations.

    Eligibility Criteria

    -Older adults (65+)

    -Able to complete the on-line questionnaires (we accept that this will limit participants to mild dementia)

    - Has access to headphones (either in ear or over ear)

    - Ability to speak English

    Recruitment End Date